€23.7m market cap

€1.5 last close

Deinove is a biotech company that discovers, develops and manufactures compounds of industrial interest stemming from rare bacteria and intended for the health, nutrition and beauty markets.

Investment summary

FY18 has been a pivotal year for Deinove with the launch of two products in its cosmetic division and a number of deals. These include the acquisition of Morphochem’s clinical-stage antibiotic DNV3837 (formerly MCB3837) and R&D collaboration agreements with Naicons, bioMérieux and Calibr. The launch of a second, internally developed carotenoid product is planned in 2019, while the initiation of the Phase II trial with DNV3837, expected later this year, will be a milestone R&D event. The company raised €8.5m in 2018 and renewed the equity line with Kepler Cheuvreux to enable it to launch a Phase II clinical trial for the Morphochem compound and finance its other activities. Our forecasts are under review.

Y/E Dec
Revenue (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2016A 0.8 (6.4) (7.7) (72.6) N/A N/A
2017A 0.2 (8.5) (9.7) (67.7) N/A N/A
2018E N/A N/A N/A N/A N/A N/A
2019E N/A N/A N/A N/A N/A N/A
Last updated on 21/02/2019
Industry outlook

Environmentalism will underpin growth in green chemistry and growing antimicrobial resistance to current antibiotics will demand the discovery of new antibiotic structures.

Last updated on 21/02/2019
Share price graph
Balance sheet
Forecast net debt (€m) N/A
Forecast gearing ratio (%) N/A
Price performance
Actual (9.6) (15.7) (38.4)
Relative* (14.9) (18.9) (36.4)
52-week high/low €4.4/€1.4
*% relative to local index
Key management
Dr Philippe Pouletty Chairman
Emmanuel Petiot CEO
Julien Coste CFO